Holen Sie sich die Stockscreener-App
1.675
2.05%
-0.035
Entera Bio Ltd Aktie (ENTX) Neueste Nachrichten
Take the Zacks Approach to Beat the Market: Dell, Caterpillar, Amkor in Focus - TradingView
Price to earnings forward of Entera Bio Ltd. – NASDAQ:ENTX - TradingView
Price to earnings forward of Entera Bio Ltd. – FWB:5DT - TradingView
Enterprise value to revenue forward of Entera Bio Ltd. – NASDAQ:ENTX - TradingView
Price to sales forward of Entera Bio Ltd. – FWB:5DT - TradingView
Enterprise value to revenue forward of Entera Bio Ltd. – FWB:5DT - TradingView
Enterprise value to EBIT forward of Entera Bio Ltd. – LSX:A2JQXP - TradingView
Price to book forward of Entera Bio Ltd. – NASDAQ:ENTX - TradingView
Price to sales forward of Entera Bio Ltd. – LSX:A2JQXP - TradingView
Enterprise value to revenue forward of Entera Bio Ltd. – LSX:A2JQXP - TradingView
Entera Bio Ltd. Actuals & Estimates (HAM:5DT) - TradingView
ENTX Forecast — Price Target — Prediction for 2027 - TradingView
5DT Forecast — Price Target — Prediction for 2027 - TradingView
H.C. Wainwright reiterates Entera Bio stock rating on FDA feedback - Investing.com UK
H.C. Wainwright reiterates Entera Bio stock rating on FDA feedback By Investing.com - Investing.com Australia
H.C. Wainwright Maintains Entera Bio(ENTX.US) With Buy Rating, Maintains Target Price $9 - Moomoo
Positive FDA Feedback on Phase 3 Brings Entera Bio's Oral Osteoporosis Pill One Step Closer to Market - GlobeNewswire Inc.
3 Promising Penny Stocks With Market Caps Under $600M - simplywall.st
ENTX Stock Pops As Entera Bio Showcases ENDO 2026 Pipeline - timothysykes.com
ENTX stock on track for best day in over 5 years — what’s driving the rally? - MSN
ENTX Stock On Track For Best Day In Over 5 Years — What’s Driving The Rally? - Yahoo Finance
FDA backs Entera Bio’s 750-patient osteoporosis trial for EB613 - Stock Titan
With Positive FDA Feedback on Phase 3, Entera Bio Just Got the Answer the Market Was Waiting For - TipRanks
Entera Bio Advances Oral Osteoporosis Drug EB613 With Positive FDA Feedback - marketscreener.com
Entera Bio Receives Positive FDA Feedback on 12-Month Registrational Phase 3 Study for EB613the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis - The Manila Times
Entera Bio Receives Positive FDA Feedback on 12-Month - GlobeNewswire
Entera Bio Ltd (ENTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Entera Bio Ltd (ENTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Entera Bio Ltd (ENTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
After Novo Nordisk's Oral Peptide Playbook Made History – Could Entera be The Next Big Peptide Story? - Benzinga
After Novo Nordisk’s Oral Peptide Playbook Made History – Could Entera be The Next Big Peptide Story? - TipRanks
Entera Bio Ltd (ENTX) Valuation: PE, PB & Fair Value Analysis - TradingKey
ENTX SEC FilingsEntera Bio Ltd 10-K, 10-Q, 8-K Forms - Stock Titan
Entera Bio Ltd (ENTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Entera Bio Ltd (ENTX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Entera Bio Ltd (ENTX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Entera Bio Ltd (ENTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Entera Bio Ltd (ENTX) Institutional Confidence - TradingKey
Entera Bio reports preclinical data for two oral peptide programs By Investing.com - Investing.com South Africa
Entera Bio reports preclinical data for two oral peptide programs - Investing.com UK
Entera Reports Robust Preclinical Data for EB612 (Oral - GlobeNewswire
Experimental oral hormone pills aim at hypoparathyroidism, obesity - Stock Titan
Entera Bio Ltd. (ENTX) Presents at Endocrine Society's Annual Meeting (ENDO 2026)Slideshow - Seeking Alpha
Entera Bio presents Phase 1 data on single-tablet EB613 By Investing.com - Investing.com South Africa
Entera Bio presents Phase 1 data on single-tablet EB613 - Investing.com
ENDO 2026 Oral Presentation Highlights Comparative Clinical - GlobeNewswire
ENDO 2026 Oral Presentation Highlights Comparative Clinical Data for Entera’s Breakthrough Single Tablet EB613 (First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis) - Yahoo Finance
Entera Bio (ENTX) Q1 2026 Earnings: Narrowed Loss Beats Estimates as Pipeline AdvancesMargin Expansion Trends - newsline.com
Entera Bio (ENTX) Slides 4.1% as Selling Pressure Tests Key Support at $1.11Long Term Entry Picks - newsline.com
ENTX Q1 2026 Earnings: Surprise EPS Beat as Operating Loss NarrowsEarnings Beat Alert - newsline.com
ENTX | Entera Bio Ltd. Ordinary Executive Compensation - Quiver Quantitative
Entera Bio (ENTX) Holds Steady at $1.22 as Stock Consolidates Near SupportFactor Rotation - dars.gov.et
[ARS] Entera Bio Ltd. SEC Filing - Stock Titan
Entera Bio (NASDAQ: ENTX) 2026 proxy seeks board, equity plan and share capital approvals - Stock Titan
Entera Bio | ARS: Annual Report to Security Holders - Moomoo
Entera Bio Is Building the Future of Peptides Beyond the Needle (NASDAQ: ENTX) - The Globe and Mail
1.60%
3.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):